Pacira Pharmaceuticals (PCRX) Posts Narrower than Expected Q3 Loss; Guides FY11 Revs
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q3 EPS of ($0.55), $0.04 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $3.96 million versus the consensus estimate of $3.97 million.
Sees FY2011 revenue of $14-$16 million, versus the consensus of $15.50 million.
Sees FY2011 revenue of $14-$16 million, versus the consensus of $15.50 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
- Hewlett Packard Enterprise (HPE) Tops Q3 EPS by 19c; raises guidance
- Five Below (FIVE) Tops Q2 EPS by 35c, Beats on Revenue; Offers Q3 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
